Literature DB >> 16699963

Private-sector research ethics: marketing or good conflicts management? The 2005 John J. Conley Lecture on Medical Ethics.

Rebecca Dresser1.   

Abstract

Pharmaceutical companies are major sponsors of biomedical research. Most scholars and policymakers focus their attention on government and academic oversight activities, however. In this article, I consider the role of pharmaceutical companies' internal ethics statements in guiding decisions about corporate research and development (R&D). I review materials from drug company websites and contributions from the business and medical ethics literature that address ethical responsibilities of businesses in general and pharmaceutical companies in particular. I discuss positive and negative uses of pharmaceutical companies' ethics materials and describe shortcomings in the companies' existing ethics programs. To guide employees and reassure outsiders, companies must add rigor, independence, and transparency to their R&D ethics programs.

Mesh:

Year:  2006        PMID: 16699963     DOI: 10.1007/s11017-005-5289-5

Source DB:  PubMed          Journal:  Theor Med Bioeth        ISSN: 1386-7415


  14 in total

1.  America's other drug problem: how the drug industry distorts medicine and politics.

Authors:  Arnold S Relman; Marcia Angell
Journal:  New Repub       Date:  2002-12-16

2.  Some questions about the moral responsibilities of drug companies in developing countries.

Authors:  D W Brock
Journal:  Dev World Bioeth       Date:  2001-05       Impact factor: 2.294

3.  Clinical trial registration: a statement from the International Committee of Medical Journal Editors.

Authors:  Catherine De Angelis; Jeffrey M Drazen; Frank A Frizelle; Charlotte Haug; John Hoey; Richard Horton; Sheldon Kotzin; Christine Laine; Ana Marusic; A John P M Overbeke; Torben V Schroeder; Hal C Sox; Martin B Van Der Weyden
Journal:  N Engl J Med       Date:  2004-09-08       Impact factor: 91.245

Review 4.  Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis.

Authors:  Bruce M Psaty; Curt D Furberg; Wayne A Ray; Noel S Weiss
Journal:  JAMA       Date:  2004-11-22       Impact factor: 56.272

5.  Potential for conflict of interest in the evaluation of suspected adverse drug reactions: a counterpoint.

Authors:  Brian L Strom
Journal:  JAMA       Date:  2004-11-22       Impact factor: 56.272

6.  Clinical trials. Facing criticism, industry offers to share data.

Authors:  Jennifer Couzin
Journal:  Science       Date:  2005-01-14       Impact factor: 47.728

7.  Gag clauses in clinical-trial agreements.

Authors:  Robert Steinbrook
Journal:  N Engl J Med       Date:  2005-05-26       Impact factor: 91.245

8.  Despite vow, drug makers still withhold data.

Authors:  Alex Berenson
Journal:  N Y Times Web       Date:  2005-05-31

9.  Tailoring arthritis therapy in the wake of the NSAID crisis.

Authors:  Nancy J Olsen
Journal:  N Engl J Med       Date:  2005-06-23       Impact factor: 91.245

10.  A new era in drug regulation?

Authors:  Rebecca Dresser
Journal:  Hastings Cent Rep       Date:  2005 May-Jun       Impact factor: 2.683

View more
  2 in total

1.  Stem cell research as innovation: expanding the ethical and policy conversation.

Authors:  Rebecca Dresser
Journal:  J Law Med Ethics       Date:  2010       Impact factor: 1.718

Review 2.  Bone regeneration: stem cell therapies and clinical studies in orthopaedics and traumatology.

Authors:  Enrique Gómez-Barrena; Philippe Rosset; Ingo Müller; Rosaria Giordano; Carmen Bunu; Pierre Layrolle; Yrjö T Konttinen; Frank P Luyten
Journal:  J Cell Mol Med       Date:  2011-06       Impact factor: 5.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.